CLAIMS

1. The use of 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of breast, bladder, colon, rectal or liver cancer;
provided that the use is not in combination with an immune checkpoint inhibitor.

2. The use according to claim 1 wherein 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide is the sole pharmaceutically active agent.

3. The use according to any one of claims 1 to 2 wherein the cancer is a breast cancer.

4. The use according to any one of claims 1 to 2 wherein the cancer is a bladder cancer.

5. The use according to any one of claims 1 to 2 wherein the cancer is a colon cancer.

6. The use according to any one of claims 1 to 2 wherein the cancer is a rectal cancer.

7. The use according to any one of claims 1 to 2 wherein the cancer is a liver cancer.

8. The use according to any preceding claim wherein cancer cells are eliminated.

9. The use according to any preceding claim wherein tumour mass is reduced.

10. The use according to any preceding claim wherein a human or animal subject having the breast, bladder, colon, rectal or liver cancer has an SDF-1 level of at least 10 FPKM.

11. The use according to any preceding claim wherein a sample from a human or animal subject having the breast, bladder, colon, rectal or liver cancer has an SDF-1 level of at least 10 FPKM.

12. The use according to claim 10 or 11 wherein the SDF-1 level is at least 11 FPKM.

13. The use according to claim 10 or 11 wherein the SDF-1 level is at least 12 FPKM.

14. The use according to claim 10 or 11 wherein the SDF-1 level is at least 13 FPKM.

15. The use according to claim 10 or 11 wherein the SDF-1 level is at least 14 FPKM.

16. The use according to claim 10 or 11 wherein the SDF-1 level is at least 15 FPKM.

17. The use according to claim 10 or 11 wherein the SDF-1 level is at least 16 FPKM.